Erb-b2 receptor tyrosine kinase 2

Overview

Erb-b2 receptor tyrosine kinase 2 (ERBB2), commonly designated HER2 (Human Epidermal Growth Factor Receptor 2), is a transmembrane receptor tyrosine kinase belonging to the ErbB/HER family of epidermal growth factor receptors. Unlike other members of this family, HER2 lacks a known endogenous ligand and instead functions primarily as a preferred dimerization partner for the remaining receptors (EGFR/HER1, HER3, and HER4). Upon heterodimerization—most notably with HER3—HER2 undergoes conformational activation that initiates downstream signaling through the RAS/MAPK, PI3K/AKT, and JAK/STAT3 pathways, driving cellular proliferation, survival, differentiation, and migration. The ERBB2 gene is located on chromosome 17q12 and encodes a 185 kDa glycoprotein comprising an extracellular domain, a single transmembrane segment, and an intracellular kinase domain. Amplification or overexpression of ERBB2 is a well-characterized oncogenic event detected across multiple tumor types, most prominently breast and gastric cancers, where it correlates with aggressive disease biology, elevated recurrence rates, and diminished overall survival.

The clinical significance of HER2 derives both from its value as a diagnostic and prognostic biomarker and from its utility as a therapeutic target. Overexpression of HER2 protein or amplification of the ERBB2 gene defines a molecularly distinct cancer subtype amenable to targeted intervention. The advent of anti-HER2 monoclonal antibodies such as trastuzumab and pertuzumab, small-molecule tyrosine kinase inhibitors (TKIs), and more recently antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1) has transformed the therapeutic landscape for HER2-positive malignancies. Ongoing research continues to expand the targetable indication set, optimize combination strategies, and address mechanisms of acquired resistance.

Recent Publications Focus

Below is a summary of the newest research publications targeting Erb-b2 receptor tyrosine kinase 2 (sorted by publication date).

Recent publications demonstrate the continued importance of HER2 as a therapeutic target across multiple cancer types. In gastric and gastroesophageal junction cancer, several trials have evaluated HER2-targeted approaches: trastuzumab combined with pembrolizumab and chemotherapy showed clinically meaningful overall survival improvement in the KEYNOTE-811 trial, with a median OS of 20.0 months versus 16.8 months in the placebo arm. Zanidatamab, a bispecific HER2-targeted antibody, demonstrated encouraging efficacy as first-line therapy when combined with chemotherapy, with or without tislelizumab. In non-small cell lung cancer, zongertinib, a selective HER2 tyrosine kinase inhibitor, achieved a 76% objective response rate and median progression-free survival of 14.4 months in patients with HER2-mutant disease. trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, has been evaluated in combination with pertuzumab for HER2-positive gastric cancer, with preclinical data suggesting enhanced antitumor activity through dual targeting of HER2 and HER3 pathways.

Antibody-drug conjugate (ADC) development has emerged as a major focus, with multiple novel engineering approaches targeting HER2. Site-specific trastuzumab Fab-based ADCs incorporating DM1 via butelase-1 ligation and albumin-binding domain fusion showed superior tumor growth inhibition compared to non-ABD analogues in HER2-positive xenografts with good tolerability. A modular UPTAB platform demonstrated simultaneous degradation of HER2 alongside other membrane proteins (EGFR, c-MET, PD-L1), with Type-I UPTAB achieving approximately 80% tumor growth inhibition in breast cancer xenografts. Trastuzumab Rezetecan, a novel HER2-targeted ADC, is being evaluated in phase I trials for HER2-expressing advanced gastric, gastroesophageal junction, and colorectal cancers. Additionally, artificial intelligence-driven approaches using generative pre-trained transformers identified novel HER2-binding antibodies with enhanced tumoricidal activity compared to trastuzumab.

Immunotherapeutic strategies targeting HER2 have advanced substantially. HER2-specific CAR-T cells engineered to produce antigen-inducible IL-12 demonstrated enhanced antitumor activity in gastric cancer models, with the regulated IL-12 secretion system achieving tumor control comparable to constitutive producers while preserving proliferative potential. A bispecific antibody targeting both HER2 and CLEC5A, a pattern recognition receptor on macrophages, showed promise in enhancing anti-HER2 therapy by altering the immunosuppressive tumor microenvironment. Mechanistic studies revealed that HER2 signaling enhances mitochondrial bioenergetics despite reductions in mitochondrial protein content, with lapatinib attenuating mitochondrial respiration in HER2-driven mammary tumors, suggesting HER2-linked activation of respiratory capacity supports tumorigenesis.

Resistance to HER2-targeted therapy remains clinically significant. In colorectal cancer liver metastases treated with anti-EGFR-based chemotherapy, comprehensive mutational profiling revealed a high frequency of potential anti-EGFR resistance mutations including ERBB2 amplifications (24.1%), alongside mutations in FGFR2 and PDGFR. Biophysical characterization of cancer-associated ErbB2 missense mutations (R143Q, R678Q, V842I) demonstrated that these variants promote a pre-dimerized receptor state with accelerated lateral mobility. To overcome trastuzumab resistance, plant-derived kaempferitrin potentiated trastuzumab efficacy in HER2-positive gastric cancer by targeting cyclooxygenase-2 to inhibit ERK signaling. Dual covalent inhibitors targeting both EGFR and HER2 achieved potent and selective inhibition through irreversible covalent binding, inducing G0/G1-phase cell cycle arrest, apoptosis, and reactive oxygen species production in NSCLC models.

Diagnostic and detection innovations for HER2 assessment have advanced significantly. A proximity-driven 3D DNA aptasensor demonstrated superior performance in distinguishing HER2-positive cancer cells and resolving diagnostically challenging immunohistochemistry 2+ cases with high consistency with fluorescence in situ hybridization. High-throughput biosensors incorporating dual-mode detection systems achieved ultrahigh sensitivity for HER2 detection with limits of detection as low as 4.3 femtograms per milliliter. A comprehensive GigaAssay platform achieved 100% accuracy in classifying HER2 gain-of-function and wild-type variants by measuring HER2 phosphorylation at Y1248. Radiomics prediction models using 18F-FDG PET/MR imaging have been developed to noninvasively identify HER2 status in colorectal cancer. Circulating tumor-DNA minimal residual disease assessment following neoadjuvant therapy in HER2-positive breast cancer may provide superior risk stratification, with deep learning solutions now enabling automated HER2 status subtyping from histopathology whole slide images.

Background PMIDs

• [PMID 41512917]
• [PMID 41789558]
• [PMID 41789591]
• [PMID 41903301]
• [PMID 41978393]
• [PMID 41985129]
• [PMID 42044055]
• [PMID 42126571]
• [PMID 42141178]
• [PMID 42201919]
• [PMID 42372741]
• [PMID 42379740]
• [PMID 42406760]

Result PMIDs

• [PMID 42009233]

Target PMIDs

• [PMID 41229221]
• [PMID 41448537]
• [PMID 41576297]
• [PMID 41779980]
• [PMID 41785602]
• [PMID 41790455]
• [PMID 41797190]
• [PMID 41805422]
• [PMID 41841313]
• [PMID 41854154]
• [PMID 41875675]
• [PMID 41886811]
• [PMID 41905552]
• [PMID 41915435]
• [PMID 41927445]
• [PMID 41957002]
• [PMID 41978393]
• [PMID 41986730]
• [PMID 42026958]
• [PMID 42029682]
• [PMID 42055709]
• [PMID 42060865]
• [PMID 42060950]
• [PMID 42068538]
• [PMID 42082270]
• [PMID 42083729]
• [PMID 42089475]
• [PMID 42096332]
• [PMID 42125775]
• [PMID 42138807]
• [PMID 42141145]
• [PMID 42175401]
• [PMID 42202319]
• [PMID 42217113]
• [PMID 42224209]
• [PMID 42263332]
• [PMID 42302265]
• [PMID 42384122]
• [PMID 42406708]